BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 23132946)

  • 1. MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia.
    Jiang X; Huang H; Li Z; He C; Li Y; Chen P; Gurbuxani S; Arnovitz S; Hong GM; Price C; Ren H; Kunjamma RB; Neilly MB; Salat J; Wunderlich M; Slany RK; Zhang Y; Larson RA; Le Beau MM; Mulloy JC; Rowley JD; Chen J
    Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19397-402. PubMed ID: 23132946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of MLL-fusion/MYC⊣miR-26⊣TET1 signaling circuit in MLL-rearranged leukemia.
    Huang H; Jiang X; Wang J; Li Y; Song CX; Chen P; Li S; Gurbuxani S; Arnovitz S; Wang Y; Weng H; Neilly MB; He C; Li Z; Chen J
    Cancer Lett; 2016 Mar; 372(2):157-65. PubMed ID: 26791235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged Disease.
    Li Z; Chen P; Su R; Hu C; Li Y; Elkahloun AG; Zuo Z; Gurbuxani S; Arnovitz S; Weng H; Wang Y; Li S; Huang H; Neilly MB; Wang GG; Jiang X; Liu PP; Jin J; Chen J
    Cancer Res; 2016 Feb; 76(3):619-29. PubMed ID: 26747896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia-rearranged leukemia.
    Chen P; Price C; Li Z; Li Y; Cao D; Wiley A; He C; Gurbuxani S; Kunjamma RB; Huang H; Jiang X; Arnovitz S; Xu M; Hong GM; Elkahloun AG; Neilly MB; Wunderlich M; Larson RA; Le Beau MM; Mulloy JC; Liu PP; Rowley JD; Chen J
    Proc Natl Acad Sci U S A; 2013 Jul; 110(28):11511-6. PubMed ID: 23798388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia.
    Li Z; Huang H; Chen P; He M; Li Y; Arnovitz S; Jiang X; He C; Hyjek E; Zhang J; Zhang Z; Elkahloun A; Cao D; Shen C; Wunderlich M; Wang Y; Neilly MB; Jin J; Wei M; Lu J; Valk PJM; Delwel R; Lowenberg B; Le Beau MM; Vardiman J; Mulloy JC; Zeleznik-Le NJ; Liu PP; Zhang J; Chen J
    Nat Commun; 2012 Feb; 3():688. PubMed ID: 22353710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs.
    Bindels EM; Havermans M; Lugthart S; Erpelinck C; Wocjtowicz E; Krivtsov AV; Rombouts E; Armstrong SA; Taskesen E; Haanstra JR; Beverloo HB; Döhner H; Hudson WA; Kersey JH; Delwel R; Kumar AR
    Blood; 2012 Jun; 119(24):5838-49. PubMed ID: 22553314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-155 is upregulated in MLL-rearranged AML but its absence does not affect leukemia development.
    Schneider E; Staffas A; Röhner L; Krowiorz K; Heuser M; Döhner K; Bullinger L; Döhner H; Fogelstrand L; Rouhi A; Kuchenbauer F; Palmqvist L
    Exp Hematol; 2016 Dec; 44(12):1166-1171. PubMed ID: 27619068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PBX3 is essential for leukemia stem cell maintenance in MLL-rearranged leukemia.
    Guo H; Chu Y; Wang L; Chen X; Chen Y; Cheng H; Zhang L; Zhou Y; Yang FC; Cheng T; Xu M; Zhang X; Zhou J; Yuan W
    Int J Cancer; 2017 Jul; 141(2):324-335. PubMed ID: 28411381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initiation of MLL-rearranged AML is dependent on C/EBPα.
    Ohlsson E; Hasemann MS; Willer A; Lauridsen FK; Rapin N; Jendholm J; Porse BT
    J Exp Med; 2014 Jan; 211(1):5-13. PubMed ID: 24367003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TGIF1 is a negative regulator of MLL-rearranged acute myeloid leukemia.
    Willer A; Jakobsen JS; Ohlsson E; Rapin N; Waage J; Billing M; Bullinger L; Karlsson S; Porse BT
    Leukemia; 2015 May; 29(5):1018-31. PubMed ID: 25349154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-106b~25 cluster is upregulated in relapsed MLL-rearranged pediatric acute myeloid leukemia.
    Verboon LJ; Obulkasim A; de Rooij JD; Katsman-Kuipers JE; Sonneveld E; Baruchel A; Trka J; Reinhardt D; Pieters R; Cloos J; Kaspers GJ; Klusmann JH; Zwaan CM; Fornerod M; van den Heuvel-Eibrink MM
    Oncotarget; 2016 Jul; 7(30):48412-48422. PubMed ID: 27351222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PBX3 is an important cofactor of HOXA9 in leukemogenesis.
    Li Z; Zhang Z; Li Y; Arnovitz S; Chen P; Huang H; Jiang X; Hong GM; Kunjamma RB; Ren H; He C; Wang CZ; Elkahloun AG; Valk PJ; Döhner K; Neilly MB; Bullinger L; Delwel R; Löwenberg B; Liu PP; Morgan R; Rowley JD; Yuan CS; Chen J
    Blood; 2013 Feb; 121(8):1422-31. PubMed ID: 23264595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TET1 plays an essential oncogenic role in MLL-rearranged leukemia.
    Huang H; Jiang X; Li Z; Li Y; Song CX; He C; Sun M; Chen P; Gurbuxani S; Wang J; Hong GM; Elkahloun AG; Arnovitz S; Wang J; Szulwach K; Lin L; Street C; Wunderlich M; Dawlaty M; Neilly MB; Jaenisch R; Yang FC; Mulloy JC; Jin P; Liu PP; Rowley JD; Xu M; He C; Chen J
    Proc Natl Acad Sci U S A; 2013 Jul; 110(29):11994-9. PubMed ID: 23818607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential regulation of the c-Myc/Lin28 axis discriminates subclasses of rearranged MLL leukemia.
    Chen L; Sun Y; Wang J; Jiang H; Muntean AG
    Oncotarget; 2016 May; 7(18):25208-23. PubMed ID: 27007052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of miR-196b is not exclusively MLL-driven but is especially linked to activation of HOXA genes in pediatric acute lymphoblastic leukemia.
    Schotte D; Lange-Turenhout EA; Stumpel DJ; Stam RW; Buijs-Gladdines JG; Meijerink JP; Pieters R; Den Boer ML
    Haematologica; 2010 Oct; 95(10):1675-82. PubMed ID: 20494936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALOX5 exhibits anti-tumor and drug-sensitizing effects in MLL-rearranged leukemia.
    Wang Y; Skibbe JR; Hu C; Dong L; Ferchen K; Su R; Li C; Huang H; Weng H; Huang H; Qin X; Jin J; Chen J; Jiang X
    Sci Rep; 2017 May; 7(1):1853. PubMed ID: 28500307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meis1 is critical to the maintenance of human acute myeloid leukemia cells independent of MLL rearrangements.
    Liu J; Qin YZ; Yang S; Wang Y; Chang YJ; Zhao T; Jiang Q; Huang XJ
    Ann Hematol; 2017 Apr; 96(4):567-574. PubMed ID: 28054140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HOX expression patterns identify a common signature for favorable AML.
    Andreeff M; Ruvolo V; Gadgil S; Zeng C; Coombes K; Chen W; Kornblau S; Barón AE; Drabkin HA
    Leukemia; 2008 Nov; 22(11):2041-7. PubMed ID: 18668134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-130b and miR-128a are essential lineage-specific codrivers of t(4;11) MLL-AF4 acute leukemia.
    Malouf C; Antunes ETB; O'Dwyer M; Jakobczyk H; Sahm F; Landua SL; Anderson RA; Soufi A; Halsey C; Ottersbach K
    Blood; 2021 Nov; 138(21):2066-2092. PubMed ID: 34111240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MLL fusion protein-driven AML is selectively inhibited by targeted disruption of the MLL-PAFc interaction.
    Muntean AG; Chen W; Jones M; Granowicz EM; Maillard I; Hess JL
    Blood; 2013 Sep; 122(11):1914-22. PubMed ID: 23900238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.